S&P 500   4,249.15 (-0.57%)
DOW   33,381.78 (-0.71%)
QQQ   351.65 (-0.72%)
AAPL   169.48 (-1.44%)
MSFT   309.85 (-0.73%)
META   287.53 (-3.82%)
GOOGL   128.80 (+0.18%)
AMZN   125.01 (-0.77%)
TSLA   235.63 (-3.48%)
NVDA   417.69 (-0.34%)
NIO   8.36 (-0.59%)
BABA   85.60 (-0.36%)
AMD   97.03 (+1.12%)
T   14.84 (-1.20%)
F   12.28 (-1.21%)
MU   67.02 (-1.35%)
CGC   0.89 (-3.25%)
GE   110.24 (+0.28%)
DIS   79.45 (-0.75%)
AMC   7.64 (-3.41%)
PFE   32.06 (-1.05%)
PYPL   56.77 (-3.67%)
NFLX   376.36 (-0.76%)
S&P 500   4,249.15 (-0.57%)
DOW   33,381.78 (-0.71%)
QQQ   351.65 (-0.72%)
AAPL   169.48 (-1.44%)
MSFT   309.85 (-0.73%)
META   287.53 (-3.82%)
GOOGL   128.80 (+0.18%)
AMZN   125.01 (-0.77%)
TSLA   235.63 (-3.48%)
NVDA   417.69 (-0.34%)
NIO   8.36 (-0.59%)
BABA   85.60 (-0.36%)
AMD   97.03 (+1.12%)
T   14.84 (-1.20%)
F   12.28 (-1.21%)
MU   67.02 (-1.35%)
CGC   0.89 (-3.25%)
GE   110.24 (+0.28%)
DIS   79.45 (-0.75%)
AMC   7.64 (-3.41%)
PFE   32.06 (-1.05%)
PYPL   56.77 (-3.67%)
NFLX   376.36 (-0.76%)
S&P 500   4,249.15 (-0.57%)
DOW   33,381.78 (-0.71%)
QQQ   351.65 (-0.72%)
AAPL   169.48 (-1.44%)
MSFT   309.85 (-0.73%)
META   287.53 (-3.82%)
GOOGL   128.80 (+0.18%)
AMZN   125.01 (-0.77%)
TSLA   235.63 (-3.48%)
NVDA   417.69 (-0.34%)
NIO   8.36 (-0.59%)
BABA   85.60 (-0.36%)
AMD   97.03 (+1.12%)
T   14.84 (-1.20%)
F   12.28 (-1.21%)
MU   67.02 (-1.35%)
CGC   0.89 (-3.25%)
GE   110.24 (+0.28%)
DIS   79.45 (-0.75%)
AMC   7.64 (-3.41%)
PFE   32.06 (-1.05%)
PYPL   56.77 (-3.67%)
NFLX   376.36 (-0.76%)
S&P 500   4,249.15 (-0.57%)
DOW   33,381.78 (-0.71%)
QQQ   351.65 (-0.72%)
AAPL   169.48 (-1.44%)
MSFT   309.85 (-0.73%)
META   287.53 (-3.82%)
GOOGL   128.80 (+0.18%)
AMZN   125.01 (-0.77%)
TSLA   235.63 (-3.48%)
NVDA   417.69 (-0.34%)
NIO   8.36 (-0.59%)
BABA   85.60 (-0.36%)
AMD   97.03 (+1.12%)
T   14.84 (-1.20%)
F   12.28 (-1.21%)
MU   67.02 (-1.35%)
CGC   0.89 (-3.25%)
GE   110.24 (+0.28%)
DIS   79.45 (-0.75%)
AMC   7.64 (-3.41%)
PFE   32.06 (-1.05%)
PYPL   56.77 (-3.67%)
NFLX   376.36 (-0.76%)
OTCMKTS:ENDV

Endonovo Therapeutics (ENDV) Stock Forecast, Price & News

$0.01
0.00 (0.00%)
(As of 09/26/2023 ET)
Compare
Today's Range
$0.0105
▼
$0.0127
50-Day Range
$0.0095
▼
$0.0140
52-Week Range
$0.00
▼
$0.03
Volume
177,106 shs
Average Volume
39,212 shs
Market Capitalization
$4.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort Interest

ENDV stock logo

About Endonovo Therapeutics (OTCMKTS:ENDV) Stock

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

ENDV Price History

ENDV Stock News Headlines

September 26, 2023 | americanbankingnews.com
Critical Comparison: Integer (NYSE:ITGR) & Endonovo Therapeutics (OTCMKTS:ENDV)
September 23, 2023 | americanbankingnews.com
Comparing Cutera (NASDAQ:CUTR) and Endonovo Therapeutics (OTCMKTS:ENDV)
September 27, 2023 | Micro-Cap Stock Trader (Ad)
Windfall profits possible with this under-the-radar lithium stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
August 22, 2023 | finance.yahoo.com
Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution
August 8, 2023 | finance.yahoo.com
Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update
June 22, 2023 | finance.yahoo.com
New to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc.
June 22, 2023 | finance.yahoo.com
New to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc.
June 7, 2023 | finance.yahoo.com
Endonovo Pending Agreement to Develop Telehealth Division
September 27, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
May 2, 2023 | finance.yahoo.com
Endonovo Launches SofPulse® into the Veterans Administration
April 25, 2023 | finance.yahoo.com
Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies
April 13, 2023 | finance.yahoo.com
Endonovo Announces Partnership with Former NFL Dallas Cowboy Defensive Lineman
April 10, 2023 | finance.yahoo.com
Endonovo Announces Partnership with Santana Lead Singer Andy Vargas
March 29, 2023 | finance.yahoo.com
Endonovo Announces Binding Letter of Intent to Sell SofPulse® Assets to Spin-Off Company
March 23, 2023 | finance.yahoo.com
Endonovo’s SofPulse® Nears Final Stages to Receive Taiwan FDA License to Distribute in Taiwan
March 15, 2023 | finance.yahoo.com
Olympian and Champion Surfer Carlos Muñoz Turns To SofPulse® For Accelerated Recovery After Invasive Shoulder Surgery
March 9, 2023 | finance.yahoo.com
Endonovo Therapeutics (OTCMKTS:ENDV) Reaches Distribution Agreement with Academy Medical
March 6, 2023 | finance.yahoo.com
Endonovo Announces Distribution Agreement with Academy Medical
February 28, 2023 | finance.yahoo.com
Endonovo Announces Q&A with Newly-Appointed SofPulse® Medical Division President, Ira Weisberg
January 31, 2023 | finance.yahoo.com
Endonovo Retains Ocean Tomo, a Part of J.S. Held, to Provide Fairness Opinion Analysis for Medical Device Spin-Off
January 26, 2023 | finance.yahoo.com
Endonovo Partners with International Distributor for SofPulse® Line
January 23, 2023 | reuters.com
ENDV.PK - | Stock Price & Latest News | Reuters
January 19, 2023 | finance.yahoo.com
New Details on Endonovo’s Spin-Off of SofPulse, Inc.
January 9, 2023 | finance.yahoo.com
Endonovo Therapeutics Details Plan to Spin Off Medical Device Division as a Listed Public Company
January 3, 2023 | finance.yahoo.com
Endonovo Targets Dept. of Defense, VA & Federal Contracts
December 19, 2022 | finance.yahoo.com
Endonovo Announces Advancement of International “Go to Market” Initiative
December 15, 2022 | finance.yahoo.com
Endonovo Announces Plans for Spin-off of Medical IP and Assets
See More Headlines
Receive ENDV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ENDV Company Calendar

Last Earnings
8/21/2023
Today
9/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ENDV
CUSIP
N/A
CIK
1528172
Web
www.endonovo.com
Phone
(800) 489-4774
Fax
818-230-9899
Employees
1
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-18,480,000.00
Net Margins
-1,597.83%
Pretax Margin
-1,597.83%
Return on Equity
N/A
Return on Assets
-342.98%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$140,000.00
Price / Sales
28.60
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.15) per share
Price / Book
-0.08

Miscellaneous

Outstanding Shares
317,750,000
Free Float
299,926,000
Market Cap
$4.00 million
Optionable
Not Optionable
Beta
-0.09
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Alan Brian Collier (Age 57)
    Chairman, CEO, Interim CFO & Sec.
    Comp: $300k
  • Mr. Don Calabria
    VP of Operations
  • Mr. Garry Michael Kann
    Head of Corp. Devel.
  • Mr. Ira Weisberg (Age 74)
    Pres & Chief Commercial Officer of Medical Division

Key Competitors

View All Competitors













ENDV Stock - Frequently Asked Questions

How have ENDV shares performed in 2023?

Endonovo Therapeutics' stock was trading at $0.0180 at the beginning of the year. Since then, ENDV shares have decreased by 30.0% and is now trading at $0.0126.
View the best growth stocks for 2023 here.

Are investors shorting Endonovo Therapeutics?

Endonovo Therapeutics saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 1,500 shares, a decrease of 60.5% from the August 15th total of 3,800 shares. Based on an average trading volume of 179,500 shares, the days-to-cover ratio is currently 0.0 days.
View Endonovo Therapeutics' Short Interest.

How were Endonovo Therapeutics' earnings last quarter?

Endonovo Therapeutics, Inc. (OTCMKTS:ENDV) announced its earnings results on Monday, August, 21st. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.05 million for the quarter.

What other stocks do shareholders of Endonovo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Endonovo Therapeutics investors own include Chesapeake Energy (CHKAQ), Energous (WATT), Advanced Micro Devices (AMD), BioLineRx (BLRX), Ekso Bionics (EKSO), Geron (GERN), Marinus Pharmaceuticals (MRNS), Micron Technology (MU), Novavax (NVAX) and Exxon Mobil (XOM).

What is Endonovo Therapeutics' stock symbol?

Endonovo Therapeutics trades on the OTCMKTS under the ticker symbol "ENDV."

How do I buy shares of Endonovo Therapeutics?

Shares of ENDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Endonovo Therapeutics' stock price today?

One share of ENDV stock can currently be purchased for approximately $0.01.

How much money does Endonovo Therapeutics make?

Endonovo Therapeutics (OTCMKTS:ENDV) has a market capitalization of $4.00 million and generates $140,000.00 in revenue each year.

How can I contact Endonovo Therapeutics?

Endonovo Therapeutics' mailing address is 6320 CANOGA AVENUE 15TH FLOOR, WOODLAND HILLS CA, 91367. The official website for the company is www.endonovo.com. The biotechnology company can be reached via phone at (800) 489-4774, via email at sbarnes@endonovo.com, or via fax at 818-230-9899.

This page (OTCMKTS:ENDV) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -